Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
Molecular therapies and precision medicine for hepatocellular carcinoma
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …
an annual incidence of 1 million cases. Genomic studies have established the landscape of …
Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology
AB Benson, MI D'Angelica, DE Abbott… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind …
Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …
[PDF][PDF] Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma
Little is known about the transcriptomic plasticity and adaptive mechanisms of circulating
tumor cells (CTCs) during hematogeneous dissemination. Here we interrogate the …
tumor cells (CTCs) during hematogeneous dissemination. Here we interrogate the …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma
J Bruix, M Reig, M Sherman - Gastroenterology, 2016 - Elsevier
Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …
their optimal care. For individuals at risk for HCC, surveillance usually involves …
The diagnosis and treatment of hepatocellular carcinoma
J Hartke, M Johnson, M Ghabril - Seminars in diagnostic pathology, 2017 - Elsevier
Hepatocellular carcinoma is a leading cancer worldwide. Its incidence is increasing, and is
closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this …
closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this …
Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma
Background & Aims Outcomes of liver transplantation for hepatocellular carcinoma (HCC)
are determined by cancer-related and non-related events. Treatments for hepatitis C virus …
are determined by cancer-related and non-related events. Treatments for hepatitis C virus …